Clinical Chemistry
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
QUICK SEARCH:   [advanced]


     

Clinical Chemistry 44: 1964-1973, 1998;
This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in Web of Science
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Web of Science (9)
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Näslund, B.
Right arrow Articles by Bergström, J.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Näslund, B.
Right arrow Articles by Bergström, J.
Related Collections
Right arrow General Clinical Chemistry
Right arrow Proteomics and Protein Markers
(Clinical Chemistry. 1998;44:1964-1973.)
© 1998 American Association for Clinical Chemistry, Inc.

General Clinical Chemistry

Luminometric single step urea assay using ATP-hydrolyzing urease

Birgitta Näslunda, Lars Ståhle, Arne Lundin1, Björn Anderstam, Peter Arner, and Jonas Bergström

1 BioThema AB, Strandvägen 36, S-130 54 Dalarö, Sweden.
a Address correspondence to this author at: Department of Pharma Marketing, Roche AB, Liljeholmsstranden 5, Box 47327, S-100 74 Stockholm, Sweden. Fax 46-87440681; e-mail birgitta.naslund{at}roche.com.

An automatic enzyme kinetic luminometric method for determination of small quantities of urea in biological fluids and in microdialysates is presented. The method is based on the ATP-hydrolyzing urease reaction [urea amidohydrolase (ATP-hydrolyzing); EC 3.5.1.45], monitored by a luciferin-luciferase ATP reaction. The assay range is 100 pmol to 50 nmol with a detection limit of 5 µmol/L in the sample, compared with detection limits of 0.1 mmol/L in earlier spectrophotometric methods. To reduce the non-urea-dependent ATPase activity (vblank) and to increase the urea-dependent activity, 1,2-propanediol was included. Assay conditions were optimized by multivariate analysis. Recoveries of urea added to blood dialysate and plasma were 96–103%. No analytical interference of common metabolites, drugs, or other additives was observed. The total CVs (6 days and six concentrations, 1.2–21.8 mmol/L) were 3.6–8.5%. The results obtained with the present assay were highly correlated for dialysate (r = 0.979) and for plasma (r = 0.978) with those obtained by a spectrophotometric kit method with slopes of 1.02–1.03 and intercepts of 0.08–0.23 mmol/L.




The following articles in journals at HighWire Press have cited this article:


Home page
 Am. J. Pathol.Home page
M. A. Olszewski, M. C. Noverr, G.-H. Chen, G. B. Toews, G. M. Cox, J. R. Perfect, and G. B. Huffnagle
Urease Expression by Cryptococcus neoformans Promotes Microvascular Sequestration, Thereby Enhancing Central Nervous System Invasion
Am. J. Pathol., May 1, 2004; 164(5): 1761 - 1771.
[Abstract] [Full Text] [PDF]


HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Copyright © 1998 by the American Association for Clinical Chemistry.